1,489
Views
14
CrossRef citations to date
0
Altmetric
Editorial

Artificial stool transplantation: progress towards a safer, more effective and acceptable alternative

&
Pages 291-293 | Published online: 10 Jan 2014

References

  • Cohen SH, Gerding DN, Johnson S et al.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31(5), 431–455 (2010).
  • Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr. Opin. Gastroenterol. 28(1), 1–9 (2012).
  • Hensgens MP, Goorhuis A, Dekkers OM, van Benthem BH, Kuijper EJ. All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin. Infect. Dis. 56(8), 1108–1116 (2013).
  • Khanna S, Pardi DS, Aronson SL et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am. J. Gastroenterol. 107(1), 89–95 (2012).
  • Tschudin-Sutter S, Widmer AF, Perl TM. Clostridium difficile: novel insights on an incessantly challenging disease. Curr. Opin. Infect. Dis. 25(4), 405–411 (2012).
  • Denève C, Janoir C, Poilane I, Fantinato C, Collignon A. New trends in Clostridium difficile virulence and pathogenesis. Int. J. Antimicrob. Agents 33(Suppl. 1), S24–S28 (2009).
  • Walter J, Ley R. The human gut microbiome: ecology and recent evolutionary changes. Annu. Rev. Microbiol. 65, 411–429 (2011).
  • Leggett MJ, McDonnell G, Denyer SP, Setlow P, Maillard JY. Bacterial spore structures and their protective role in biocide resistance. J. Appl. Microbiol. 113(3), 485–498 (2012).
  • Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect. Control Hosp. Epidemiol. 31(1), 21–27 (2010).
  • Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol. 9(2), 88–96 (2012).
  • van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368(5), 407–415 (2013).
  • Bakken JS, Borody T, Brandt LJ et al.; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 9(12), 1044–1049 (2011).
  • Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature, 486(7402), 207–214 (2012).
  • Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 107(5), 761–767 (2012).
  • Petrof EO, Gloor GB, Vanner SJ et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 1(3), doi:10.1186/2049-2618-1-3 (2013).
  • Petrof EO, Claud EC, Gloor GB, Allen-Vercoe E. Microbial ecosystems therapeutics: a new paradigm in medicine? Benef. Microbes 4(1), 53–65 (2013).
  • Allen-Vercoe E, Reid G, Viner N et al. A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics. Can. J. Gastroenterol. 26(7), 457–462 (2012).
  • Eisenhauer N, Scheu S, Jousset A. Bacterial diversity stabilizes community productivity. PLoS ONE 7(3), e34517 (2012).
  • Kolmeder CA, de Been M, Nikkilä J et al. Comparative metaproteomics and diversity analysis of human intestinal microbiota testifies for its temporal stability and expression of core functions. PLoS ONE 7(1), e29913 (2012).
  • Morgan XC, Huttenhower C. Chapter 12: human microbiome analysis. PLoS Comput. Biol. 8(12), e1002808 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.